Top Buy Stocks
Sign In
Invest in ABEO
$5.89
-0.110 (-1.83%)
At Close: Jun 20, 2025
Abeona Therapeutics. Earnings Calls
Mar 31, 2025
-$0.240 (31.43%)
| Release date | May 15, 2025 |
| EPS estimate | -$0.350 |
| EPS actual | -$0.240 |
| EPS Surprise | 31.43% |
| Revenue estimate | - |
| Revenue actual | - |
Dec 31, 2024
-$0.240 (44.19%)
| Release date | Mar 20, 2025 |
| EPS estimate | -$0.430 |
| EPS actual | -$0.240 |
| EPS Surprise | 44.19% |
| Revenue estimate | 83.33K |
| Revenue actual | - |
Sep 30, 2024
-$0.310 (18.42%)
| Release date | Nov 14, 2024 |
| EPS estimate | -$0.380 |
| EPS actual | -$0.310 |
| EPS Surprise | 18.42% |
| Revenue estimate | 83.33K |
| Revenue actual | - |
Jun 30, 2024
-$0.750 (-127.27%)
| Release date | Aug 12, 2024 |
| EPS estimate | -$0.330 |
| EPS actual | -$0.750 |
| EPS Surprise | -127.27% |
| Revenue estimate | 80K |
| Revenue actual | - |
Last 4 Quarters for Abeona Therapeutics.
Below you can see how ABEO performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Jun 30, 2024
Missed
| Release date | Aug 12, 2024 |
| Price on release | $4.95 |
| EPS estimate | -$0.330 |
| EPS actual | -$0.750 |
| EPS surprise | -127.27% |
| Date | Price |
|---|---|
| Aug 06, 2024 | $4.68 |
| Aug 07, 2024 | $4.42 |
| Aug 08, 2024 | $4.47 |
| Aug 09, 2024 | $4.42 |
| Aug 12, 2024 | $4.95 |
| Aug 13, 2024 | $4.98 |
| Aug 14, 2024 | $4.95 |
| Aug 15, 2024 | $5.00 |
| Aug 16, 2024 | $5.00 |
| 4 days before | 5.77% |
| 4 days after | 1.01% |
| On release day | 0.606% |
| Change in period | 6.84% |
Sep 30, 2024
Beat
| Release date | Nov 14, 2024 |
| Price on release | $5.95 |
| EPS estimate | -$0.380 |
| EPS actual | -$0.310 |
| EPS surprise | 18.42% |
| Date | Price |
|---|---|
| Nov 08, 2024 | $6.40 |
| Nov 11, 2024 | $6.43 |
| Nov 12, 2024 | $6.11 |
| Nov 13, 2024 | $6.10 |
| Nov 14, 2024 | $5.95 |
| Nov 15, 2024 | $5.86 |
| Nov 18, 2024 | $5.86 |
| Nov 19, 2024 | $5.89 |
| Nov 20, 2024 | $5.75 |
| 4 days before | -7.03% |
| 4 days after | -3.36% |
| On release day | -1.51% |
| Change in period | -10.16% |
Dec 31, 2024
Beat
| Release date | Mar 20, 2025 |
| Price on release | $5.14 |
| EPS estimate | -$0.430 |
| EPS actual | -$0.240 |
| EPS surprise | 44.19% |
| Date | Price |
|---|---|
| Mar 14, 2025 | $5.29 |
| Mar 17, 2025 | $5.30 |
| Mar 18, 2025 | $5.16 |
| Mar 19, 2025 | $5.20 |
| Mar 20, 2025 | $5.14 |
| Mar 21, 2025 | $5.15 |
| Mar 24, 2025 | $5.12 |
| Mar 25, 2025 | $5.00 |
| Mar 26, 2025 | $4.99 |
| 4 days before | -2.84% |
| 4 days after | -2.92% |
| On release day | 0.195% |
| Change in period | -5.67% |
Mar 31, 2025
Beat
| Release date | May 15, 2025 |
| Price on release | $5.79 |
| EPS estimate | -$0.350 |
| EPS actual | -$0.240 |
| EPS surprise | 31.43% |
| Date | Price |
|---|---|
| May 09, 2025 | $5.27 |
| May 12, 2025 | $5.60 |
| May 13, 2025 | $5.63 |
| May 14, 2025 | $5.39 |
| May 15, 2025 | $5.79 |
| May 16, 2025 | $6.10 |
| May 19, 2025 | $6.23 |
| May 20, 2025 | $6.42 |
| May 21, 2025 | $6.45 |
| 4 days before | 9.87% |
| 4 days after | 11.40% |
| On release day | 5.35% |
| Change in period | 22.39% |
Abeona Therapeutics. Earnings Call Transcript Summary of Q1 2025
Summary of Key Points from Abeona Therapeutics Q1 2025 Earnings Call
Company Overview
- Abeona Therapeutics is now a commercial-stage cell and gene therapy company following the FDA approval of ZEVASKYN, its first product, which is a gene therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB).
- ZEVASKYN offers significant benefits such as the potential for complete wound closure and pain reduction through a single application.
Product Launch and Market Response
- The company has activated its first Qualified Treatment Center (QTC), Lurie Children’s Hospital of Chicago, which is recognized for its expertise in genetic skin diseases. The treatment is expected to begin in August 2025.
- Initial response from patients and physicians has been positive with about 30 inquiries in the first two weeks post-approval, indicating a strong unmet need.
- The company intends to activate additional QTCs across the country by the end of 2025 to broaden patient access.
Clinical Data and Safety
- Recent presentations at the Society for Investigative Dermatology showcased ZEVASKYN’s durable efficacy, including long-term wound closure and absence of cancer at treatment sites.
Financial Highlights
- As of March 31, 2025, Abeona had $84.5 million in cash and equivalents, which is expected to be bolstered by a $155 million sale of its Priority Review Voucher (PRV).
- The PRV sale proceeds will extend operational funding into early 2026, which is crucial for achieving profitability driven by ZEVASKYN.
- The net loss for the first quarter of 2025 was reported at $12 million, improved compared to $31.6 million from the previous year.
Future Goals
- Abeona aims to treat 10 to 14 patients in 2025 with ZEVASKYN and anticipates significant volume growth by 2026 as more treatment centers come online and processes are optimized.
- Discussions for outcomes-based agreements with payers are ongoing, reinforcing Abeona's commitment to ensuring access to ZEVASKYN.
Pipeline Development
- The company is on track to advance its RS1 ophthalmology program into clinical trials in the second half of 2026 while continuing to track progress across its pre-clinical programs.
Conclusion
Abeona Therapeutics is positioned for rapid growth following FDA approval of ZEVASKYN. With a promising initial response from patients and healthcare providers, and a robust financial and operational structure, the outlook for the company appears optimistic.
Abeona Therapeutics. Earnings History
Earnings Calendar
FAQ
When is the earnings report for ABEO?
Abeona Therapeutics Inc. (ABEO) has scheduled its earnings report for Aug 11, 2025 before the markets open.
What is the ABEO price-to-earnings (P/E) ratio?
ABEO P/E ratio as of Jun 20, 2025 (TTM) is -6.76.
What is the ABEO EPS forecast?
The forecasted EPS (Earnings Per Share) for Abeona Therapeutics Inc. (ABEO) for the first fiscal quarter 2025 is -$0.390.
What are Abeona Therapeutics Inc.'s retained earnings?
On its balance sheet, Abeona Therapeutics Inc. reported retained earnings of $0 for the latest quarter ending Mar 31, 2025.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
